Founded with a mission to address significant unmet clinical needs, Avivomed is a neuromodulation technology provider focused on developing and commercializing advanced therapeutic platforms. The company aims to improve the lives of patients suffering from chronic diseases through innovative neuromodulation therapies. Avivomed operates in both the United States and Ireland, targeting large patient populations with its cutting-edge medical solutions.
Avivomed has garnered support from notable investors and industry leaders, contributing to its rapid growth and development. The company has achieved significant milestones in the neuromodulation field, positioning itself as a key player in the market for chronic disease treatment. Through its pioneering technology, Avivomed has made a substantial impact on improving patient outcomes and advancing medical science in neuromodulation therapy.
